ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
ACST Stock – (NASDAQ: ACST) is giving an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the use of the “at-the market” equity of its offering plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement an “at-the market” equity offering program under which Acasti may well issue as well as promote from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares had been offered at prevailing market costs averaging US$1.0747 a share. No securities had been sold in the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and can supply the Company with more freedom in its ongoing review process to explore and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy as well as safety in lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for individuals with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release that aren’t statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims include known and unknown risks, uncertainties, and other unknown components that might cause the actual results of Acasti to be materially different from historical results and from any future results expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, people are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the day of this particular press release. Forward-looking statements in this press release include, but are not restricted to, info or statements concerning Acasti’s strategy, succeeding operations and its review of strategic options.
The forward looking claims contained in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor area of Acasti’s site at www.acastipharma.com. Most forward-looking assertions in that press release are available as of the day of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a direct result of info which is brand new, future events or otherwise, except as called for by law. The forward-looking claims contained herein are also subject typically to assumptions and risks as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage